Skip to main content

Peptide Profile

FSH

Follicle-Stimulating Hormone · follitropin · urofollitropin · Gonal-F · Follistim

FSH (follicle-stimulating hormone) is an endogenous heterodimeric glycoprotein hormone produced and secreted by pituitary gonadotrophs, composed of a non-covalently associated common alpha subunit shared with LH, TSH, and hCG,…

Reproductive & HormonalFDA ApprovedPrescription
Routes
subcutaneous, intramuscular

Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.

Educational research tools — not medical advice.

Overview

What FSH is

About FSH

Binds FSH receptors on Sertoli cells in testes to support sperm maturation and inhibin B production. In women, binds granulosa cell FSH receptors to drive follicular growth and estradiol production.

FSH (follicle-stimulating hormone) is an endogenous heterodimeric glycoprotein hormone produced and secreted by pituitary gonadotrophs, composed of a non-covalently associated common alpha subunit shared with LH, TSH, and hCG, and a unique FSH-specific beta subunit that confers receptor specificity; it is the primary regulator of gametogenesis in both sexes, acting on ovarian granulosa cells and testicular Sertoli cells to drive reproductive development. FSH activates its cognate receptor (FSHR) through cAMP-mediated signaling to stimulate follicular maturation and estradiol synthesis in the ovary via aromatase upregulation, and to support spermatogenesis in the testis by promoting Sertoli cell function and germ cell proliferation; FSH levels rise dramatically at menopause as negative feedback from ovarian estrogen declines. A Cochrane systematic review and meta-analysis established that recombinant FSH preparations are clinically equivalent to urinary-derived gonadotropins for ovarian stimulation in assisted reproductive technology cycles, providing the evidence base underlying current ART practice; this review supports the use of recombinant FSH as the standard of care for controlled ovarian hyperstimulation. FDA-approved recombinant FSH preparations — follitropin alfa (Gonal-f) and follitropin beta (Follistim) — require a prescription and are indicated for ovulation induction and ART in women and for hypogonadotropic hypogonadism in men; endogenous FSH is not administered as a therapeutic agent, and research-grade recombinant FSH is used as a cell culture tool and reproductive biology research compound.

Women's Health

Recombinant FSH is the evidence-based standard for ovulation induction and controlled ovarian stimulation in ART. FDA-approved recombinant preparations (follitropin alfa/Gonal-f, follitropin beta/Follistim) carry a Pregnancy Category X-equivalent contraindication under the Menopur label class — FSH/menotropin products are not used in established pregnancy. FSH has no evidenced role in menopause treatment; in fact the endogenous-biology direction relevant to menopause is FSH blockade, studied only in mice.

FSH Benefits & Research Areas

spermatogenesisfertility supportfollicular developmentovarian stimulation
The Research

What the evidence says about FSH

Research Evidence

Established Clinical

based on 12 studies · most recent 2026

Regulatory Status

Availability Status
Prescription
FDA Status
FDA Approved
Effective Date
September 29, 1997

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Research Sources

12 sources cited · 2 strong · 10 moderate

2 Meta-analysis · 9 Cohorts · 1 Review

  • Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles

    Cochrane Database of Systematic Reviews · 2011

    This Cochrane meta-analysis of 42 randomized controlled trials involving 9,606 couples found no statistically significant difference in live birth rate between recombinant FSH and urinary gonadotrophins (OR 0.97, 95% CI 0.87-1.08) for ovarian stimulation in IVF and ICSI cycles, establishing clinical equivalence and informing FSH preparation selection based on availability and cost.

    Meta-analysisn=9,606StrongPMID 21328276
  • Efficacy and safety of hMG versus recombinant FSH: a meta-analysis

    Reprod Biomed Online · 2008

    Meta-analysis establishing recombinant FSH efficacy/safety for ovulation induction in ART.

    Meta-analysisStrongPMID 18252052
  • Revisiting ESR in PCOS: an easily obtainable link to immune and metabolic dysregulation.

    J Ovarian Res · 2026

    CohortModeratePMID 42374565
Show 9 more sources
  • [Association between sex hormone levels and high-sensitivity C-reactive protein in older adults aged 65 years and above in 18 longevity areas in China].

    Zhonghua Liu Xing Bing Xue Za Zhi · 2026

    CohortModeratePMID 42373476
  • [Association between sex hormone levels and high-sensitivity C-reactive protein in older adults aged 65 years and above in 18 longevity areas in China].

    Zhonghua Liu Xing Bing Xue Za Zhi · 2026

    CohortModeratePMID 42373476
  • The improvement of umbilical cord mesenchymal stem cells on the ovarian microenvironment: a systematic review and meta-analysis.

    J Ovarian Res · 2026

    # Summary This systematic review and meta-analysis found that umbilical cord mesenchymal stem cell (UCMSC) transplantation in mouse models of premature ovarian failure significantly decreased serum follicle-stimulating hormone (FSH) levels while simultaneously increasing estradiol and anti-Müllerian hormone levels. Research also demonstrated that UCMSC transplantation increased the number of follicles at multiple developmental stages (primordial, primary, secondary, and antral follicles) in these animal models.

    CohortModeratePMID 42216054
  • Functional Landscape of Zebrafish Gonadotropins and Receptors: A Comprehensive Genetic Analysis.

    Genetics · 2026

    CohortModeratePMID 42376857
  • Recovery of gonadal axis in patients with prolactinomas.

    Exp Clin Endocrinol Diabetes · 2026

    # Summary Research found that in prolactinoma patients treated with cabergoline, the hypothalamic-pituitary-gonadal axis—measured by markers including FSH levels—normalized over an average of 82 days, with recovery time significantly influenced by initial prolactin levels, patient gender, and age. This study demonstrated that understanding these factors is important for predicting the timeline of gonadal axis recovery in prolactinoma management.

    CohortModeratePMID 42214441
  • Menopause and vascular endothelial health: Is it all about the oestrogen?

    Exp Physiol · 2026

    # Summary This study demonstrated that the cardiovascular risks associated with menopause extend beyond estrogen decline alone, with rising FSH levels also contributing to vascular endothelial dysfunction through mechanisms involving endothelin-1 signaling, oxidative stress, and inflammatory pathways. Research found that understanding the effects of multiple sex hormones—including FSH, progesterone, and LH—is essential to fully explain the accelerated cardiovascular disease risk observed in menopausal women.

    ReviewModeratePMID 42218087
  • Molecular analysis of FSHR rs6166 polymorphism and oxidative stress parameters in women with polycystic ovary syndrome.

    Mol Biol Rep · 2026

    CohortModeratePMID 42377768
  • Lycopene ameliorates acrylamide-induced reproductive toxicity through enhancement in testicular antioxidant status and upregulation of androgen receptor expression in male Wistar rats.

    BMC Pharmacol Toxicol · 2026

    # Summary Research found that lycopene improved reproductive function in rats exposed to acrylamide by enhancing antioxidant defenses in testicular tissue and increasing the expression of androgen receptors, while also restoring hormonal balance including follicle-stimulating hormone (FSH) levels. This study demonstrated that lycopene's protective mechanisms involved reducing oxidative stress markers and improving sperm quality parameters in acrylamide-exposed male rats.

    CohortModeratePMID 42216064
  • Functional Landscape of Zebrafish Gonadotropins and Receptors: A Comprehensive Genetic Analysis.

    Genetics · 2026

    CohortModeratePMID 42376857

FSH Side Effects & Safety Considerations

Contraindications below are derived from the compound’s FDA label. Educational only — not medical advice.

Absolute contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Common monitoring markers in research protocols

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Frequently Asked Questions — FSH

FSH (follicle-stimulating hormone) is an endogenous heterodimeric glycoprotein hormone produced and secreted by pituitary gonadotrophs, composed of a non-covalently associated common alpha subunit shared with LH, TSH, and hCG, and a unique FSH-specific beta subunit that confers receptor specificity; it is the primary regulator of gametogenesis in both sexes, acting on ovarian granulosa cells and testicular Sertoli cells to drive reproductive development. FSH activates its cognate receptor (FSHR) through cAMP-mediated signaling to stimulate follicular maturation and estradiol synthesis in the ovary via aromatase upregulation, and to support spermatogenesis in the testis by promoting Sertoli cell function and germ cell proliferation; FSH levels rise dramatically at menopause as negative feedback from ovarian estrogen declines.

spermatogenesis, fertility support, follicular development, ovarian stimulation, HPG axis.

Research on FSH primarily documents effects related to spermatogenesis and fertility support and follicular development and ovarian stimulation and HPG axis. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For FSH, its FDA status is FDA-approved, and it is available by prescription. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

This Cochrane meta-analysis of 42 randomized controlled trials involving 9,606 couples found no statistically significant difference in live birth rate between recombinant FSH and urinary gonadotrophins (OR 0.97, 95% CI 0.87-1.08) for ovarian stimulation in IVF and ICSI cycles, establishing clinical equivalence and informing FSH preparation selection based on availability and cost.

Access

How to get FSH

Where to buy FSH

Coverage expanding

No verified providers currently list FSH. Get notified when one does, or explore providers carrying similar peptides in the Sexual Health category.

Questions to ask your provider

Stay updated on verified FSH providers

New verified providers added weekly — delivered to your inbox.

Weekly research digest. No spam. Unsubscribe anytime.

Last updated

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.